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ABSTRACT
Introduction: Tacrolimus (Tac) is effective in preventing acute rejection but has considerable toxicity
and inter-individual variability in pharmacokinetics and pharmacodynamics. Part of this is explained by
polymorphisms in genes encoding Tac-metabolizing enzymes and transporters. A better understanding
of Tac pharmacokinetics and pharmacodynamics may help to minimize different outcomes amongst
transplant recipients by personalizing immunosuppression.
Areas covered: The pharmacogenetic contribution of Tac metabolism will be examined, with a focus
on recent discoveries, new developments and ethnic considerations.
Expert opinion: The strongest and most consistent association in pharmacogenetics is between the
CYP3A5 genotype and Tac dose requirement, with CYP3A5 expressers having a ~ 40–50% higher dose
requirement compared to non-expressers. Two recent randomized-controlled clinical trials using
CYP3A5 genotype, however, did not show a decrease in acute rejections nor reduced toxicity.
CYP3A4*22, CYP3A4*26, and POR*28 are also associated with Tac dose requirements and may be
included to provide the expected improvement of Tac therapy. Studies focusing on the intracellular
drug concentrations and on calcineurin inhibitor-induced nephrotoxicity also seem promising. For all
studies, however, the ethnic prevalence of genotypes should be taken into account, as this may
significantly impact the effect of pre-emptive genotyping.
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1. Introduction
The calcineurin inhibitor (CNI) tacrolimus (Tac) is used to pre-
vent acute rejection after solid organ transplantation (SOT).[1]
Unfortunately, the clinical use of Tac is complicated by its
considerable toxicity, narrow therapeutic window, and high
interindividual pharmacokinetic variability.[2] Therapeutic
drug monitoring (TDM) is universally applied to individualize
Tac therapy in SOT recipients. However, despite TDM, many
SOT recipients experience significant over- or underexposure
to Tac. Part of the interindividual variability in Tac pharmaco-
kinetics is explained by genetic polymorphisms in genes
encoding for Tac metabolizing enzymes and transporter pro-
teins.[3–5] Genetic variation may also explain interindividual
differences in Tac’s pharmacodynamics. In this article, the
relevance of a pharmacogenetic approach to Tac therapy is
discussed. The focus is on recent discoveries, new develop-
ments, and ethnic considerations.
2. Genetic variation and Tac pharmacokinetics
Tac is a substrate of the drug-efflux pump ABCB1 (encoded by
the ABCB1 gene), which is expressed in the intestine and
thought to limit the absorption of Tac. Interindividual differ-
ences in the expression and/or function of ABCB1 determines
the variability in the bioavailability of Tac.[6] Following absorp-
tion, Tac is metabolized in the intestine, liver, and to a limited
degree in the kidney by cytochrome P450 (CYP) 3A4 and 3A5.
[7] Interindividual differences in CYP3A activity are the most
important determinants of the variability in Tac clearance.
Other enzymes/receptors including P450 oxidoreductase
(POR), the nuclear receptor peroxisome proliferator-activated
receptor alpha (PPAR-α), and CYP2C8 play minor roles in the
disposition of Tac. Nonetheless, polymorphisms in PPARA, POR,
and CYP2C8 may explain residual variability in the response
to Tac.
2.1. CYP3A5
Polymorphisms in the CYP3A5 gene explain 40–50% of the
variability in Tac dose requirement.[8,9] The best studied sin-
gle-nucleotide polymorphism (SNP) in CYP3A5 is CYP3A5*3,
which is an A to G transition at position 6986 within intron 3
(rs776746). The CYP3A5*3 allele causes alternative splicing,
which results in protein truncation and a severe decrease of
functional CYP3A5 enzyme.[10] Other CYP3A5 SNPs are
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CYP3A5*6 (rs10264272) and CYP3A5*7 (rs41303343): CYP3A5*6
encodes a 14690G>A transition, causing a splice variant mRNA
and deletion of exon 7, resulting in nonfunctional CYP3A5
protein. [10,11] CYP3A5*7 denotes a single base insertion at
codon 346 causing a frameshift, resulting in a truncated mRNA
and nonfunctional CYP3A5.[12]
Individuals homozygous for the CYP3A5*3 allele are
referred to as CYP3A5 non-expressers, whereas individuals
carrying at least one CYP3A5*1 allele are known as CYP3A5
expressers. The reduced enzymatic activity associated with the
CYP3A5*3 allele has been associated with a reduced Tac dose
requirement (for a review, see reference [13]). CYP3A5 expres-
sers require a Tac dose that is about 50% higher than that of
CYP3A5 non-expressers to reach the same exposure. This is a
consistent finding and has been observed in both adults and
children, and among recipients of either a kidney, liver, heart,
or lung transplant.[14–16]
Following standard, bodyweight-based dosing, CYP3A5
expressers are prone to have subtherapeutic Tac concentra-
tions in the early phase after surgery and may therefore be at
an increased risk for acute rejection. MacPhee et al.[17]
demonstrated that CYP3A5 expressers did indeed have a
delay in achieving the target Tac exposure, in spite of TDM.
However, CYP3A5 expressers did not experience more biopsy-
proven acute rejection, although rejection did occur earlier in
CYP3A5 expressers compared with non-expressers with a
median of 7 versus 13 days.[17] Other investigators have also
reported that CYP3A5 expressers do not have a higher risk of
developing acute rejection.[18–26]
Although numerous studies have reported the higher Tac
dose requirement of CYP3A5 expressers compared to non-
expressers, the clinical relevance of this association is unclear
and has so far only been investigated in two randomized-con-
trolled clinical trials (RCT). The Tactique study [27] was a multi-
center RCT, including 280 renal transplant recipients. Patients
were randomized 1:1 to receive either a standard starting dose
of Tac (0.1 mg/kg twice daily) or a starting dose based on an
individual patient’s CYP3A5 genotype (0.075 or 0.15 mg/kg
twice daily for CYP3A5 non-expressers and expressers, respec-
tively). The primary efficacy endpoint was the proportion of
patients for whom the Tac predose concentration (C0) was
within the target range (10–15 ng/mL) after six unchanged
doses of Tac. In the Tactique study, this was day 10 because
Tac was started on day 7 after transplantation. Throughout the
first post-transplant week, all patients were Tac-free to allow for
CYP3A5 genotyping, and received high-dose mycophenolate
mofetil (MMF; 3 g/day), glucocorticoids, and induction therapy
with rabbit antithymocyte globulin (rATG; in 82.2% of patients)
or IL-2 receptor antibodies (in 17.8% of patients). In the
Tactique study, CYP3A5 genotype-based Tac (start)dosing led
to significantly more patients reaching the target range 3 days
after the start of Tac treatment as compared with standard,
bodyweight-based Tac dosing: 43.2% versus 29.1%.[27] Also,
the group that received a CYP3A5 genotype-based Tac dose
needed significantly less time and fewer dose adaptations to
reach target. However, there were no differences between the
two groups with regard to graft survival, acute rejection,
delayed graft function, or Tac toxicity.[27]
Recently, the long-term follow-up results of Tactique were
published.[28] Pallet et al. reported that the incidence of
biopsy-proven acute rejection and graft survival were similar
between the control and the CYP3A5 genotype-adapted Tac
dose groups. There were also no differences between the two
groups in terms of patient survival, the incidence of cancer,
cardiovascular events, infections, and kidney function. The
authors concluded that optimization of initial Tac dosing
using CYP3A5 pharmacogenetic testing does not improve clin-
ical outcomes.[28]
In a second RCT, 240 renal transplant recipients were ran-
domized to receive a standard, bodyweight-based Tac starting
dose (0.1 mg/kg twice daily) or a CYP3A5 genotype-based
starting dose (0.075 or 0.15 mg/kg twice daily for CYP3A5
non-expressers and expressers, respectively).[29] Unlike the
Tactique study, this trial only included recipients of a living
kidney donor (who were genotyped for CYP3A5 during the
workup for transplantation) and Tac was started on the day of
transplantation rather than at day 7 post-transplant. All
patients received basiliximab induction therapy and a stan-
dard MMF starting dose of 2 g/day followed by TDM. The
primary endpoint of this trial was again the proportion of
patients within the Tac therapeutic range on day 3 after
transplantation (i.e. at first steady state). Unlike in Tactique,
there was no difference in the proportion of patients ‘on
target’ at day 3 after transplantation: 37.4% versus 35.6% for
the standard-dose and the genotype-based groups, respec-
tively. In addition, there was no difference in the time-to-
reach target concentration or the number of Tac dose mod-
ifications required to reach the target concentration. In line
with the French trial, there were no differences in any of the
clinical endpoints, including the incidence of acute rejection.
It is unknown why the CYP3A5-based Tac dosing approach
was beneficial in terms of early Tac exposure in the Tactique
study, whereas this was not the case in the second. The main
difference between these studies was the day on which Tac
was initiated (day 0 vs. 7). Changes in glucocorticoid dosing or
gastrointestinal motility during the first postoperative week
may have had a greater effect on Tac exposure than CYP3A5
genotype. Of note, in both studies, the percentage of patients
‘on target’ 3 days after initiation of Tac was low in spite of
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CYP3A5 genotype adaptation. This observation demonstrates
that there exists considerable residual variability in Tac phar-
macokinetics that is not explained by CYP3A5 genotype. The
fact that neither study demonstrated a clinical benefit, does
not support routinely genotyping kidney transplant recipients
for CYP3A5. Possibly, donor genotype (including that of
CYP3A5) may be more relevant for long-term clinical outcome
than the genotype of the recipient.[30]
2.2. CYP3A4
The CYP3A4 SNPs CYP3A4*1B (rs2740574) and CYP3A4*22
(rs35599367) have both been associated with altered Tac
dose requirements. Individuals carrying the CYP3A4*1B allele
were reported to have a 35% lower Tac dose-adjusted C0
compared to individuals having the CYP3A4 wild-type allele.
[31–33] However, whether the CYP3A4*1B allele is truly itself
responsible for the altered Tac dose requirement remains a
matter of debate as this SNP is in linkage disequilibrium with
the CYP3A5*1 allele.[34]
CYP3A4*22 (rs35599367) is located in intron 6 of CYP3A4
and is a C to T substitution at g.15389. Wang and Sadee [35]
demonstrated that CYP3A4*22 increases the formation of the
nonfunctional CYP3A4 splice variant with partial intron 6
retention, thereby reducing the production of functional full-
length CYP3A4 mRNA and reduced CYP3A4 enzymatic activity.
Elens et al. [36] were the first to find that the CYP3A4*22
variant is associated with lower Tac dose requirements after
renal transplantation. When CYP3A4 and CYP3A5 genotypes of
individual patients were combined, Elens et al. were able to
predict Tac dose requirements better compared with the
CYP3A4 or CYP3A5 genotype alone. Based on these observa-
tions, it has been proposed to prescribe different Tac doses for
ultrarapid (CYP3A5 expressers and CYP3A4*1/*1), intermediate
(CYP3A5 non-expressers and CYP3A4*1/*1) and poor (CYP3A5
non-expressers and CYP3A4*22 carriers) CYP3A metabolizers,
respectively.[36–38] In pediatric heart transplantation, an asso-
ciation between CYP3A4*22 and Tac dose requirement has
also been observed.[39] CYP3A4*22 carriers needed 30% less
Tac to reach similar target concentrations compared with
CYP3A4*1/*1 carriers.
Recently a new and rare CYP3A4 variant was described, which
is now designated as CYP3A4*26.[40] This variant is a c.802C>T
transition and results in a premature stop codon at position 268
in exon 9 (R268*).[40] The resulting truncated CYP3A4 protein is
nonfunctional. Werk et al. [41] first identified this mutation when
they observed an unusually low Tac dose requirement in a
kidney transplant recipient. This patient had very high Tac expo-
sure following standard Tac dosing and only reached the ther-
apeutic window once the Tac dose was reduced to 0.5 mg thrice
weekly. This patient was a CYP3A5*3 homozygote and was also
homozygous for CYP3A4*26, and therefore experienced com-
plete failure of CYP3A enzyme activity.
2.3. POR
POR is a protein that functions as an electron donor for CYP
enzymes (including CYP3A) and is essential for CYP-mediated
drug oxidation.[42] More than 100 SNPs have been identified in
the human POR gene and these may influence POR–CYP inter-
action and CYP activity.[42,43] The POR*28 SNP (rs1057868; C>T)
induces an amino acid substitution (p.Ala503Val) at position 503
which influences the electron binding moiety of POR and likely
modifies its interaction with CYP enzymes.[42–44] Individuals
homozygous for POR*28 have an increased in vivo CYP3A activ-
ity with regard to midazolam compared with wildtype POR.[45]
In a study in 71 healthy Chinese volunteers, Zhang et al.
[46] demonstrated that CYP3A5 expressers carrying the
POR*28 variant allele had a Tac exposure that was about
40% lower than CYP3A5 expressers with wildtype POR. The
increased Tac dose requirement of CYP3A5-expressing kid-
ney transplant recipients carrying the POR*28 (T) variant
allele was recently confirmed by Elens and Lunde et al.
[47,48] Taken together, these studies suggest that the
POR*28 SNP leads to increased CYP3A5-mediated Tac meta-
bolism, possibly resulting from a facilitated interaction
between POR, CYP3A5, and Tac. In CYP3A5 non-expressers,
Tac metabolism depends entirely on CYP3A4 and POR*28
apparently does not influence CYP3A4 activity to a clinically
relevant degree.
2.4. ABCB1
ABCB1 is thought to be responsible for the low oral bioavail-
ability of Tac and is also considered important for the distribu-
tion of Tac throughout the body and its excretion into bile and
urine.[49] The ABCB1 gene contains more than 50 SNPs of
which the 3435C>T (rs1045642), 1236C>T (rs1128503), and
2677G>T/A (rs2032582) SNPs, which are in linkage disequili-
brium, have received the most attention. The functional sig-
nificance of these SNPs on ABCB1 expression and function
remains unclear. It has been suggested that the synonymous
ABCB1 3435C>T SNP affects the timing of co-translational
folding and insertion of ABCB1 into the membrane, thereby
altering the structure of substrate and inhibitor sites.[50]
Many studies have investigated the influence of ABCB1
SNPs on Tac pharmacokinetics but results are conflicting and
suggest no or at best a limited impact of ABCB1 SNPs on Tac
exposure. For an extensive review of these studies, the reader
is referred to the literature.[51]
Because ABCB1 is also expressed in the membrane of
lymphocytes, its activity may also impact the intracellular
accumulation of Tac where the drug exerts its biologic
effect. Vafadari et al. [52] found that patients with the
ABCB1 3435CC genotype need more Tac for inhibition of
IL-2 production in T cells compared with 3435TT genotype
patients. Capron et al. demonstrated that patients carrying
the ABCB1 3435T or the 2677T/A allele had 1.3-fold higher
Tac concentrations within circulating lymphocytes com-
pared with wildtype homozygotes.[53] These studies pro-
vide evidence that ABCB1 3435C>T and 2677G>T/A affect
Tac distribution into lymphocytes with the variant alleles
being associated with an increased pharmacodynamic effect
of Tac. In line with the above, ABCB1 SNPs also may be
relevant with regard to its nephrotoxicity, because tissue
concentrations of Tac are believed to be related to its
renal side effects (see Section 3.1).
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2.5. PPAR-α and PXR
The nuclear receptor peroxisome proliferator-activated recep-
tor alpha (PPAR-α) has recently been recognized as potential
contributor to intra- and interindividual variability in CYP3A
expression and activity. Two sequence variants in the PPAR-α
gene (PPARA) can affect PPAR-α expression. In vitro, PPARA
c.209-1003G>A and c.208+3819A>G were associated with
reduced expression of PPAR-α, and consistently related to
lower CYP3A4 mRNA levels, protein expression, and enzymatic
activity.[54] Recently, Lunde et al. found that expression of at
least one PPARA variant allele was significantly associated with
a higher Tac C0/D ratio, when adjusting for POR*28, CYP3A5*3,
and CYP3A4*22 among 229 kidney transplant recipients.[48] A
detailed analysis of the two PPARA sequence variants showed
significantly increased Tac exposure in patients homozygous
for PPARA-α c.209-1003G>A. These results are in concordance
with the reduced CYP3A4 protein/activity levels previously
observed in vitro.[54] At present, PPARA c.208+3819A>G
appears to be the PPARA sequence variant with the strongest
influence on Tac pharmacokinetics but this observation
requires confirmation.
The human pregnane X receptor (PXR; encoded by NR1I2),
is a nuclear transcription factor that regulates the expression
of CYP3A and ABCB1. Several SNPs in NR1I2 have been identi-
fied but conflicting results regarding their association with Tac
dose requirement have been reported.[8,55,56]
3. Genetic variation and clinical outcomes
Tac treatment is accompanied by adverse effects, including
nephrotoxicity (both acute and chronic), posttransplant dia-
betes mellitus (PTDM), neurotoxicity, and hypertension. With
TDM the majority of patients can be brought within the
targeted window quite rapidly after transplantation.
Nevertheless, some patients will experience acute rejection
or Tac toxicity, despite being within the target range, reflect-
ing differences in Tac pharmacodynamics. The relationship
between genetic variation and Tac pharmacodynamics is the
subject of the second part of this review.
3.1. Nephrotoxicity
Acute CNI-induced nephrotoxicity is caused by constriction of
the afferent glomerular arteriole leading to a reduced renal
blood flow and glomerular filtration rate (GFR). Chronic CNI-
induced nephrotoxicity appears to be the result of structural
changes in the kidney caused by chronic changes in renal
hemodynamics. CNI-induced nephrotoxicity is likely to be
related to intra-renal concentrations of CNIs which may not
be properly reflected by whole-blood CNI concentrations.[57–
60] CYP3A5 is the only CYP3A isozyme expressed in the kidney
and may limit local exposure to CNIs by intra-renal metabo-
lism.[61,62] Zheng et al. [63] demonstrated that Tac concen-
trations in the renal epithelium of CYP3A5 expressers are 53%
lower compared with CYP3A5 non-expressers.
Studies on the relationship between CYP3A5 genotype and
the risk of Tac-induced nephrotoxicity have reported contra-
dictory results. Kuypers et al.[32] observed a higher incidence
of biopsy-proven Tac-nephrotoxicity (defined as de novo arter-
iolar hyalinization) in CYP3A5-expressing kidney transplant
recipients. In a follow-up study, which included more patients
(n = 304), this group confirmed that CYP3A5 expressers have
an increased risk for biopsy-proven Tac-induced nephrotoxi-
city.[64] These counter-intuitive findings may be explained by
the fact that it is not Tac itself but its metabolites that are
responsible for its nephrotoxicity. These metabolites might be
formed at an increased rate in the renal parenchyma of
CYP3A5 expressers. However, there is at present little evidence
to support this hypothesis.
In contrast to the studies by the Leuven group, a Chinese
study including 67 kidney recipients showed a higher inci-
dence of nephrotoxicity in CYP3A5 non-expressers at 1-
month posttransplant.[65] In patients with the CYP3A5*3/*3
genotype, interstitial fibrosis and proximal tubular vacuoliza-
tion were more severe than in patients with the CYP3A5*1/*3
genotype. Similarly, in a study with 136 renal transplant reci-
pients (121 Caucasians, 12 Africans, and 3 Asians), those with
the CYP3A5*3/*3 genotype tended to have a higher incidence
of biopsy-proven nephrotoxicity compared to CYP3A5*1 allele
carriers, although the difference was nonsignificant.[66] There
are many reasons for these discrepancies, including differ-
ences in ethnicity, sample size, and the definition of
nephrotoxicity.
ABCB1 is expressed in the apical membrane of renal
tubular epithelial cells, where it may facilitate excretion of
CNIs (and their metabolites) in urine and thus protect the
kidney against intra-renal CNI accumulation. Studies on the
relationship between ABCB1 genotype and the risk of Tac-
induced nephrotoxicity are more consistent compared with
those on CYP3A5. In a prospective cohort study of 252 renal
transplant recipients Naesens et al.[57] observed a progres-
sive increase in glomerulosclerosis, vascular intimal thicken-
ing and IF/TA over the first 3 years posttransplantation. A
lower ABCB1 expression in kidney transplant biopsies was a
risk factor for such chronic histologic damage in patients
receiving Tac. In another study they reported that both
donor and recipient homozygosity for ABCB1 3435TT was
associated with a higher risk of Tac-associated kidney
damage.[67] Combined donor-recipient ABCB1 3435TT
homozygosity was also a risk factor for worse graft function
after the first posttransplant year. The authors speculated
that the relevance of the recipient genotype could possibly
be explained by renal epithelial chimerism in the allograft.
Recently, in a study including 368 African-American and 314
European American deceased donors, Ma et al. found that
the T allele at ABCB1 3435 of the kidney donor is associated
with shorter renal allograft survival compared with 3435C for
kidneys from European American donors. [68] A poorer renal
function (i.e. a lower estimated GFR) was also observed
among patients who received kidneys from donors with
the ABCB1 3435TT genotype as compared with patients
receiving ABCB1 3435CC kidneys.[69]
In contrast, Moore et al. reported contradictory results. In a
very large cohort (n = 4471 white kidney transplant recipients),
it was the 3435CC donor genotype (not 3435TT as in the study
by Ma et al.) that was associated with a worse death-censored
graft survival.[70]
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The discrepancies between these studies are unexplained.
Again differences in sample size, patient characteristics, and
duration of follow-up may form an explanation. Perhaps more
importantly, loss of renal function may have causes other than
chronic CNI nephrotoxicity and in many of the larger genetic
association studies, ‘pure’ chronic CNI nephrotoxicity was not
distinguished from, for example, recurrent primary kidney dis-
ease, chronic rejection, or polyomavirus-associated nephropa-
thy.[13] Finally, and perhaps most importantly, there is no
‘gold standard’ to diagnose chronic CNI nephrotoxicity. Even
renal histology has its shortcomings and is not specific
enough for making a definitive diagnosis.[71] Possibly, in the
future, we will see an increasing use in genetic association
studies of surrogate markers for the chronic nephrotoxic
effects of CNIs. Preliminary data indicate that markers of
epithelial-to-mesenchyme transition may serve as such.[72]
Some studies have investigated the association between
CNI-nephrotoxicity and genetic variation in genes other than
ABCB1 and CYP3A. One such gene is CYP2C8, which is a mem-
ber of the P450 superfamily and is expressed in the kidney
where it is involved in the metabolism of arachidonic acid to
biologically active epoxyeicosatrienoic acids (EETs). EETs help
to maintain blood pressure, are involved in tubular reabsorp-
tion of water and sodium transport, protect against inflamma-
tion, and the maintenance of vascular smooth muscle tone.
[73–75] Smith et al. [76] found that patients carrying one or
more CY2C8*3 variant alleles have a higher risk of developing
CNI-induced nephrotoxicity after liver transplantation.
Possibly, decreased production of EETs in patients with the
variant CYP2C8*3 allele may reduce the capacity of their kid-
neys to counter the vasoconstrictive effects of CNIs. Gervasini
et al. observed that the rs1042032A>G SNP in EPHX2, the gene
that encodes soluble epoxy hydrolase, the enzyme which
metabolizes EETs to less active compounds, was associated
with renal allograft function and the risk of acute rejection.[77]
3.2. Delayed graft function
Delayed graft function (DGF) is most commonly defined as the
need for dialysis within the first week after transplantation.
[78,79] It is associated with reduced long-term allograft survi-
val and is closely related to ischemia/reperfusion injury.[78,80]
Hauser et al. [81] investigated the impact of ABCB1, ABCC2,
and PXR polymorphisms of the donor and recipient on the
development of DGF after renal transplantation. The PXR
8055TT genotype of the donor (but not the recipient) was
significantly associated with an increased risk of DGF.
Another study, including 304 kidney transplant recipients
found that DGF was associated with higher initial Tac expo-
sure which occurred more frequently in CYP3A5 non-expres-
sers.[82] A recent study in renal transplant patients found that
the CYP3A4*22 allele was associated with a higher risk of DGF
compared with CYP3A4*1 homozygotes in cyclosporine (CsA)-
treated patients.[83] There are no reports on the association
between CYP3A4*22 and DGF in patients treated with Tac.
More recently, Gervasini et al.[84] investigated the association
between DGF and the CYP2C8*3 variant allele. They observed
that subjects carrying one or two CYP2C8*3 variant alleles had
a higher risk of developing DGF and had a lower creatinine
clearance 1 year after transplantation than CYP2C8*1/*1
homozygotes.[84]
3.3. Acute rejection
The incidence of acute rejection may be related to genetic
variation in the genes encoding the proteins involved in the
absorption and elimination of immunosuppressive drugs
(reviewed in references [3,51]). However, at present, no con-
sistent association between CYP3A and ABCB1 SNPs and an
individual’s risk for rejection has been demonstrated and the
additional risk posed by certain genetic variants, if any,
appears to be small and is unlikely to be clinically relevant.
[85,86] That these studies did not find CYP3A5 genotype to be
associated with the risk of acute rejection may be perceived as
a surprise, given the strong influence of CYP3A5 genotype on
Tac dose requirement. It thus seems that the very efficient
process of TDM results in rapid correction of Tac concentra-
tions outside the target range. As a result the genotype-
induced underexposure only lasts for a few days, which is
not sufficient to cause a clinically important increased inci-
dence of acute rejection episodes.[87]
3.4. PTDM
PTDM is a frequent complication of Tac therapy.[88] Tac is
directly toxic to islets of Langerhans and impairs insulin secre-
tion and insulin gene expression.[88] A patient’s genetic back-
ground may contribute to the risk of PTDM. Among 101 renal
transplant recipients receiving Tac-based immunosuppressive
therapy, Elens et al. found that the PPARA rs4253728A>G and
POR*28 variant alleles were both independently associated
with an increased risk of developing PTDM with respective
odds ratios of 8.6 (95%CI 1.4–54.2) and 8.1 (95%CI 1.1–58.3).
[89] Several other investigators have reported associations
between the risk of PTDM and polymorphisms in the vitamin
D receptor gene, promoter region of the IL-6 gene, transcrip-
tion factor 7-like 2 gene (rs7903146), and the zinc transporter-
8 gene (SLC30A8; rs13266634).[90–94]
The role of pharmacogenetics in PTDM is complex. CNIs,
glucocorticoids, and mTOR inhibitors are all diabetogenic but
alternative immunosuppressive regimens (including anti-pro-
liferative agents and the novel immunosuppressant belata-
cept) have been associated with higher rejection rates.[95]
Possibly, genetic risk factors may be used together with non-
genetic variables to estimate an individual’s risk of developing
PTDM. However, even if this becomes possible in the future,
the current literature does not provide guidance on what the
best immunosuppressive regimen would be for such patients.
4. Other Tac-related adverse events
Tac can cause hypertension and is neurotoxic. Tac causes
hypertension by activating the renal sodium chloride co-trans-
porter, which is under the control of the ‘with-no-lysine’(WNK)
kinase network. Ferrarresso et al. genotyped 92 Caucasian
kidney transplant recipients receiving CsA or Tac and found
that CYP3A5*1 carriers had a higher blood pressure 1 week
and 6 months after transplantation.[96] Torio et al. also found
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a trend toward higher blood pressure in CYP3A5*1 carriers
treated with a CNI, 6 and 24 months after kidney transplanta-
tion.[97] At present, it appears that CYP3A5 genotype may
relate to an individual’s risk of developing hypertension but
there is no convincing evidence that SNPs in ABCB1, WNK4, or
SPAK do the same (see reference [98] for an extensive review
on the genetic basis of hypertension).
Using pharmacogenetics to guide antihypertensive therapy
in Tac-treated patients appears to be more readily clinically
applicable. Diltiazem is a calcium channel antagonist that
interacts with Tac by inhibiting CYP3A-mediated Tac metabo-
lism. Kidney transplant patients expressing CYP3A5 were
much more susceptible to the inhibitory effects of diltiazem
than non-expressers.[99]
Neurotoxic effects of Tac include tremor, headache, insomnia,
and peripheral neuropathy.[100] Although the exact pathophy-
siology of Tac-induced neurotoxicity is unclear, penetration of
Tac into the central nervous system (CNS) is considered impor-
tant. ABCB1 is an important component of the blood brain
barrier and loss of its function leads to accumulation of Tac in
the CNS, at least in mice.[101,102] However, no clinically mean-
ingful associations between ABCB1 genotype and the risk of
developing Tac-induced neurotoxicity have been identified.
Yamauchi et al.[103] found that transplant recipients carrying
the ABCB1 2677T/A allele had an increased risk of neurotoxicity,
whereas carriers of an ABCB1 3435T allele had a decreased risk.
Yanagimachi et al. [104] reported that among 30 pediatric
patients who received CsA for the prevention of graft-versus-
host disease the ABCB1 1236CC genotype tended to be asso-
ciated with neurotoxicity after adjustment for age, hypertension,
and renal dysfunction (P = 0.07). In the same study, the CYP3A5*1
allele was found to be associated with an increased risk for
neurotoxicity. Yanagimachi et al. suggested that it may not be
Tac itself but its metabolites that cause neurotoxicity. Such
metabolites might be formed locally at an increased rate in
CYP3A5 expressers. An increased risk for neurotoxicity in associa-
tion with the ABCB1 1236C or 2677G alleles was also observed by
a Spanish research group.[24] Prospective studies that measure
Tac concentrations in the cerebrospinal fluid of affected patients
may shed more light on the pathophysiology of Tac-induced
neurotoxicity and the role of genetic variation therein.
5. Ethnic considerations
Ethnicity may play an important role in interindividual variability
of drug metabolism and response. Genetic variations of drug-
metabolizing enzymes show pronounced differences between
populations. Allelic frequencies of the most common SNPs in
CYP3A5, CYP3A4, ABCB1, and POR*28 in various ethnic groups are
presented in Table 1. The most striking difference is the marked
variation in the allelic frequency of the CYP3A5*3 allele which is
common among Caucasian patients but less frequently seen in
patients of Asian or African descent. Patients of African descent
require higher doses of Tac to reach the target concentration
range. Vadivel et al. found that for patients of African descent a
Tac starting dose of 0.3 mg/kg per day is probablymore effective
than the currently recommended starting dose of 0.2 mg/kg per
day.[105] This higher dose requirement appears to result in part
from the high number of CYP3A5 expressers among patients of
African descent.[106]
The lower exposure to Tac following standard dosing may
be responsible for the higher acute rejection risk after kidney
transplantation in recipients of African descent.[112] By con-
trast, CYP3A5 genotype appears not to be a risk factor for the
poorer long-term kidney allograft survival observed in patients
of African descent, despite its well-characterized influence on
Tac dose requirement.[113]
In addition to CYP3A5*3, the CYP3A5*6 and CYP3A5*7
variant alleles can also lead to the absence of functional
CYP3A5 protein. These SNPs are rare or absent in Asian or
Caucasian populations, but are found commonly in African
populations. The presence of CYP3A5*6 and CYP3A5*7 in
African populations may compensate for the relatively low
frequency of the CYP3A5*3 allele, resulting in a metabolic
phenotype similar to that of Caucasians. The guidelines
recommend increasing the starting dose by 1.5–2 times in
extensive metabolizers (CYP3A5*1/*1) and intermediate
metabolizers (CYP3A5*1/*3, *1/*6, or *1/*7) and to prescribe
a standard dose in poor metabolizers (CYP3A5*3/*3, *6/*6,
*7/*7, *3/*6, *3/*7, or *6/*7).[114] This recommendation is
supported by the findings of a study in African-American
kidney transplant recipients (n = 354). In this study, it was
observed that *6 and *7 allele carriers required lower Tac
doses. In this African-American population, one or more
nonfunctional CYP3A5 alleles (*3, *6, or *7) were identified
in 74.5%.[115] This study demonstrated that there are con-
siderably more CYP3A5 non-expressers in African popula-
tions than was previously presumed. In 197 adult African
kidney transplant recipients, Oetting et al.[116] also found
that the variants CYP3A5*3, CYP3A5*6, and CYP3A5*7
explained a great proportion of the observed Tac C0 varia-
bility in African recipients. Taken together, these studies
illustrate the importance ethnicity-specific genotypes
(CYP3A5*6 and CYP3A5*7) for Tac clearance. Using dosing
models that account for these genotypes may lead to a
more precise dosing of Tac.
Table 1. Allele frequencies (by ethnic group) of relevant Tac metabolizing enzymes and transporters.
Caucasians (%) Africans (%) Indians (%) Asians (%) References
CYP3A5*3 90–93 32 66, 68 60–73 [107,108]
CYP3A5*6 0–4.3 8.6–15 ND 0 [107]
CYP3A5*7 0 5–12 ND 0 [107]
CYP3A4*1B 2–9.6 35–67 3.5 0 [109]
CYP3A4*22 8.3 4.3 ND 4.3 [37,110]
ABCB1 3435C 48–62 68–83 38 51–62 [111]
ABCB1 1236C 55–59 85 ND 35–41 [111]
POR*28 26 19 30 37 [43]
ABCB1: ATP-binding cassette subfamily B member 1; CYP: Cytochrome P450; POR: Cytochrome P450 oxidoreductase.
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Given the size and ethnic diversity of the Chinese popula-
tion, it is very important to investigate the interethnic varia-
bility in this particular group. In a study of six different Chinese
ethnic groups, Lai et al. [117] found that significantly higher
frequencies of CYP3A5*3 variant alleles were observed in
Uygur Chinese (88.1%), Kazakh Chinese (84.5%), and Tibetan
Chinese (80.3%) than in Han (67.3%) and Bai Chinese (70.2%).
The lowest frequency of the CYP3A5*3 variant alleles was
observed in Wa Chinese (56.3%). This result was consistent
with what was reported previously by Li et al. [118] (Uygur
Chinese 84.8%, Kazakh Chinese 86.6%, and Han Chinese
72.7%). The frequency of the CYP3A5*3 variant allele in
Uygur, Kazakh, and Tibetan Chinese appears to be more simi-
lar to Caucasians as compared with Han Chinese. Other stu-
dies, however, did not report significant differences in the
CYP3A5*3 allelic frequency among Uygur and Kazakh Chinese
and Caucasians.[10,119,120]
The frequency of CYP3A4*1B in African-Americans (35–67%)
is the highest amongst all ethnic groups.[109] The frequencies
of the ABCB1 3435C and the 1236C alleles are also much
higher in individuals of African descent than in populations
of other ethnicity.[111] Recently, a novel CYP3A4 loss-of-func-
tion allele (CYP3A4*20) was identified and was shown to be
present in 1.2% of the Spanish population. This polymorphism
has, however, not been investigated in relation to Tac dose
requirement nor toxicity.[121,122]
In conclusion, ethnic variation in the prevalence of CYP3A5,
CYP3A4, and ABCB1 genotypes is high and clinically relevant.
Given the fact that CYP3A5 genotype has the strongest and
most consistent association with Tac dose requirement, a
CYP3A5 genotype-based Tac dosing approach may be espe-
cially relevant for patients of African descent who are more
often CYP3A5 expressers than Caucasians. How this genetic
variability affects the metabolizing phenotype in the non-
Caucasian and non-African population is incompletely under-
stood and should be the subject for future studies.
6. Dosing algorithms
Dosing algorithms have only fairly recently been proposed to
better individualize the Tac starting dose.[123] In 2011, Passey
et al. created the first dosing algorithm using a combination of
genetic information and clinical factors in adult kidney trans-
plant recipients. The algorithm included CYP3A5 genotype,
days post-transplant, age, steroid, and calcium channel
blocker use. Interestingly, other factors such as sex, ethnicity,
and bodyweight did not have a statistically significant influ-
ence on Tac clearance.[124] The dosing algorithm was later
successfully validated in an independent cohort of 795 kidney
transplant recipients.[125] In 2013, the developed dosing algo-
rithm was prospectively tested by an independent research
group in the United Kingdom. Unfortunately, the dosing algo-
rithm was not able to predict estimated Tac clearance accu-
rately.[126] As mentioned before, not all pharmacokinetic
variability is explained by the CYP3A5 genotype. It was
recently shown that the algorithm designed by Passey was
improved by incorporating the CYP3A4*22 allele.[127]
More recently, Størset et al. [128] used the dosing software
BestDose, including fat-free mass, hematocrit, time after
transplantation, Tac-dosing history and the patient’s pre-
viously measured Tac concentrations, but not CYP3A5 geno-
type, to determine the Tac starting dose in renal transplant
recipients. They found that computerized dose individualiza-
tion improved target achievement of Tac compared with con-
ventional dosing early after renal transplantation and that the
computer software may also potentially improve long-term
outcome.[128] One advantage of not basing the dose predic-
tions on genotype in this study is that it is useful also for
centers without the opportunity to perform pretransplant
genotyping. To our knowledge this dosing algorithm has not
been further tested or improved. This Norwegian study mainly
included Caucasian patients. If algorithms such as these are to
gain widespread (clinical) acceptance their performance
should not only be validated but this should also be done in
populations of different ethnicity.[128]
7. Conclusions
In conclusion, the CYP3A5 genotype of the transplant recipient
has an impact on Tac dose requirement in SOT recipients.
Other variants, such as CYP3A4*22, CYP3A4*26, and POR*28
are also associated with Tac dose requirement. Besides these
pharmacokinetic considerations, ethnicity plays an important
role in interindividual variability in Tac metabolism.
Unfortunately, the evidence that implementing genotype-
based Tac dosing will improve clinical outcome is missing.
Recent studies have shown that dosing algorithms which
incorporate genetics with demographic and clinical factors
may allow for more precise Tac dosing. However, further
research is necessary to elucidate the role of pharmacoge-
netics in the pharmacodynamic effects of Tac.
8. Expert opinion
Immunosuppressive drug therapy is necessary to prevent
acute rejection after SOT. Tac is the preferred CNI and it is to
be expected that in the next 10 years many SOT recipients will
continue to receive Tac as part of their immunosuppressive
maintenance regimen. There is convincing evidence that the
CYP3A5 and the CYP3A4 genotype of the recipient have a
significant impact on Tac dose requirement. However, despite
the strong genetic effect on Tac dose requirement, the evi-
dence that implementing genotype-based dosing will improve
clinical outcome is missing. Two RCTs using CYP3A5 genetic
information to guide Tac dosing have been performed. The
first of these showing a small increase in the proportion of
patients reaching the target Tac concentration, but without
reduction in the incidence of acute rejection, and a second
study, which even failed to show an improvement of the
achievement of the pharmacokinetic outcome parameters.
CYP3A5 is currently the strongest known genetic predictor
of Tac dose requirement, but it does not explain all variability.
Other variants, including CYP3A4*22, CYP3A4*26, and POR*28
are also associated with Tac dose requirements. These other
variants may need to be taken into consideration. Given its
proactive nature, pharmacogenetics may still be a potential
complimentary tool to TDM for optimizing immunosuppres-
sive therapy.
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A more precise and rational strategy to optimize early Tac
exposure is to use a dosing algorithm that incorporates more
than just the bodyweight and CYP3A5 genotype. Such dosing
algorithms may include genetics and demographic and clinical
factors. Although the implementation of dosing algorithms is
appealing, they do have some limitations. The developed
dosing algorithms are all very different and many have not
been validated in independent data sets. Most algorithms are
published in pharmacokinetic journals, which make them less
accessible to clinicians. Refining of Tac dose prediction is
possible using dosing algorithms. We propose that newly
developed dosing algorithms for the starting dose need to
be validated and subsequently tested in an independent
cohort of patients. If successful, a clinical trial should be con-
ducted with the amount of patients on target on day 3 after
initiation as primary endpoint. Clearly, the rapid adjustment of
Tac dose based on TDM can correct for any variability in Tac
exposure resulting from genetic differences within a matter of
days. Therefore, it is questionable if the transplant community
will adopt the strategy of genotyping recipients prior to trans-
plantation for these metabolizing enzymes and transporters.
To get the most out of the efficacy and safety of Tac, more
effort has to be put into a better understanding of pharmaco-
genetics of the pharmacodynamic effects of the drug. It has
been demonstrated that ABCB1 and CYP3A5 expression within
the kidney transplant is associated with CNI-induced nephro-
toxicity. However, with regard to the other toxic effects of Tac,
like hypertension, neurotoxicity, and PTDM, the results about
the relationship between these side effects and pharmacoge-
netics are conflicting and seem to be of little value for the
clinician. Prospective studies using novel techniques such as
mass spectrometry to detect Tac metabolites and tissue drug
concentrations should be developed to elucidate the role of
pharmacogenetics in Tac nephrotoxicity. Possibly, genetic
information may predict the occurrence of drug toxicity and
provide guidance to clinicians to choose for Tac-free or
reduced-dose Tac immunosuppressive protocols in those at
high risk.[129,130]
Ethnicity plays an important role in interindividual variabil-
ity of drug metabolism and response. Where Caucasian
patients are mostly CYP3A5 non-expressers, patients from
Asian descent are CYP3A5 expressers in about one-third of
cases, and those from African descent in two-thirds of cases.
Preemptive genotyping for CYP3A5 or other relevant Tac
metabolizing enzymes may be more promising in ethnic
populations containing higher proportions of expressers. The
two prospective randomized trials were both performed in
populations containing largely Caucasian patients.
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